Adasuve will now be launched in Sweden, Norway, Finland and Denmark

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that Adasuve now will be
launched for the treatment of mild to moderate agitation of patients with
schizophrenia or bipolar disorder. Medivir entered a license and distribution
agreement for the commercialization of Adasuve with Ferrer in September 2013.
Adasuve is a brand new inhalable treatment of agitation and is approved by EMA
(European Medicines Agency) for sale in Europe.

“It is gratifying to be able to launch Adasuve in the four main Nordic countries
as a complement to our existing product portfolio” comments Henrik Krook EVP
Commercial, Medivir.

About agitation
More than eight million of the European adult population lives with
schizophrenia and bipolar disorder. Market research in the European territory
indicates that 15-20 percent of those with schizophrenia and bipolar disorder
experience an average of two episodes of agitation each year. The goal of
treatment of agitation is to help the patient to gain control of their emotions
or anxiety, and to avoid enforcement action that might otherwise have to be used
to manage the patient's condition. The standard treatment for acute agitation
today consists of antipsychotic drugs, sometimes in combination with
benzodiazepines.

About Adasuve
Adasuve is the first inhalable drug in psychiatry. Adasuve is a non-invasive,
fast acting alternative to currently used therapies. Because of its non-invasive
form of treatment Adasuve can bring benefits to both patients and caregivers.
Adasuve combines the proprietary Staccato system with loxapine, an antipsychotic
medicinal product. The Staccato system is a hand-held inhaler that delivers a
drug aerosol to the deep lung resulting in intravenous-like pharmacokinetics and
rapid systemic effects.

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

About Medivir
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is
simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is
being developed in collaboration with Janssen R&D Ireland. The company is also
working with research and development in other areas, such as bone disorders and
neuropathic pain. Medivir has also a broad product portfolio with prescription
pharmaceuticals in the Nordics.

For more information, please visit www.medivir.com.

About Ferrer
Ferrer is a privately-held European R&D-based pharmaceutical company
headquartered in Barcelona. It is active in the pharmaceutical, health, fine
chemicals and food sectors in Europe, Latin America, Africa, the Middle East,
Asia and the United States. In total, Ferrer's human healthcare products are
commercialized in more than 90 countries, through 23 international affiliates
(including joint ventures) and 70 partners and distributors.

Ferrer carries out activities throughout the full pharmaceutical value chain,
from R&D to international marketing, including fine chemical development and the
manufacturing of both raw materials and finished pharmaceuticals. Its research
centers in Spain and Germany, and manufacturing sites in Europe and Latin
America cover the pharmaceutical, diagnostics, vaccine, fine chemical, food and
feed sectors. Ferrer holds the commercial rights for Adasuve in Europe, Latin
America and the Commonwealth of Independent States countries.

About Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA)
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions. Alexza's products are based on the Staccato®
system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung,
providing rapid systemic delivery and therapeutic onset, in a simple, non
-invasive manner.

Adasuve is Alexza's first commercial product, which was approved by the U.S.
Food and Drug Administration in December 2012 and by the European Commission in
February 2013. Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for
ADASUVE in the U.S. Grupo Ferrer Internacional, S.A. is Alexza's commercial
partner for Adasuve in Europe, Latin America and the Commonwealth of Independent
States countries. Adasuve® and Staccato® are registered trademarks of Alexza
Pharmaceuticals, Inc.